Second disappearance an “unfortunate coincidence”

Author­i­ties are inves­ti­gat­ing the dis­ap­pear­ance of a sec­ond indi­vid­ual who was who was enrolled in one of Lazar’s clin­i­cal tri­als. George Lazar, Pres­i­dent and CEO of Lazar Phar­ma­ceu­ti­cals, calls this sec­ond dis­ap­pear­ance “an unfor­tu­nate coin­ci­dence” and reit­er­ates that as of this time, “there have been no charges filed and no accu­sa­tions made regard­ing any crim­i­nal or improp­er activ­ity on behalf of Lazar Pharmaceuticals.”